Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

FDA extends IDegLira NDA review

Sep. 5, 2016

Glucox Biotech describes novel NADPH oxidase 4 inhibitors

Sep. 5, 2016

Merck & Co. discontinues development of odanacatib for osteoporosis

Sep. 5, 2016

Alnylam's ALN-AS1 receives FDA orphan drug designation

Sep. 2, 2016

European Commission approves expanded use of Xultophy

Sep. 2, 2016

Betagenon and Baltic Bio start phase IIa trial of O-304

Sep. 1, 2016

Kamada reports positive results on inhaled alpha-1 antitrypsin phase II trial

Aug. 31, 2016

Sunshine Lake Pharma describes FXR agonists

Aug. 31, 2016

Lilly generates potent and selective GOAT inhibitors for metabolic conditions

Aug. 30, 2016

Piramal Enterprises discloses GPR120 agonists

Aug. 29, 2016

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...